Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2022-11-15 Director's Dealing
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2022-11-15 English
FORM 3
Director's Dealing
2022-11-15 English
FORM 3
Director's Dealing
2022-11-15 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the appointment of a new Chief Operating Officer, Christopher Brooke, including his background and related transactions. This fits the category of announcements about changes in the company's board of directors or senior management. There is no financial data or report attached, so it is not an Annual Report or Interim Report. The document is not a proxy statement, earnings release, or other categories. Therefore, the appropriate classification is Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2022-11-15 English
424B5
Capital/Financing Update Classification · 100% confidence The document is titled 'Amendment No. 1 to Prospectus Supplement' and references a Controlled Equity Offering Sales Agreement for common stock. It discusses registration under Form S-3, aggregate offering price, and sales agent details. The content is focused on updating or amending a prospectus supplement related to a stock offering. This type of document is a capital/financing update, specifically an amendment to a prospectus supplement for a stock offering. It is not a full financial report, earnings release, or regulatory filing unrelated to financing. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 3452 characters, which is consistent with an amendment filing rather than a full report.
2022-11-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the fiscal first quarter 2023 ended September 30, 2022. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The length is 3637 characters, which is relatively short and consistent with a current report announcing earnings results rather than the full earnings release document. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). However, since this is a Form 8-K announcing the earnings release and attaching the press release, and the text states the press release is furnished as an exhibit, this is the actual earnings release announcement. The content is primarily the announcement of the earnings results and business update, which fits the Earnings Release category. Therefore, the correct classification is ER with high confidence.
2022-11-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.